Publication: Simultaneous determination of 5-hydroxytryptophan and 3-O-methyldopa in dried blood spot by UPLC-MS/MS: A useful tool for the diagnosis of L-amino acid decarboxylase deficiency
This original study article, published in the Journal of Chromatography B, outlines a study to establish a reliable method to assess both 5-hydroxytryptophan (5-HTP) and 3-O-methyldopa (3-OMD) in dried blood spot (DBS) analysis through ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) technology, for the biochemical diagnosis of AADC deficiency
Review the role of high-performance liquid chromatography (HPLC) analysis of cerebrospinal fluid (CSF) neurotransmitter metabolites in the diagnosis of AADC deficiency
Find out about a new tool for the detection of 5-HTP alongside 3-OMD in DBS for the diagnosis of AADC deficiency
Understand the mechanism behind simultaneous measurement of 5-HTP and 3-OMD in DBS and how this improves the specificity and sensitivity of the biochemical diagnosis of AADC deficiency is discussed
Di Carlo E, et al. J Chromatogr B Analyt Technol Biomed Life Sci. 2021;1185:122999
Once registered, you will be able to view the abstract and be provided the DOI and PubMed links for this publication.
▼ Eladocagene exuparvovec is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system. Adverse events should also be reported to PTC Therapeutics at email@example.com.
Eladocagene exuparvovec (UpstazaTM) is a gene therapy indicated for the treatment of patients aged 18 months and older with a clinical, molecular, and genetically confirmed diagnosis of AADC deficiency with a severe phenotype, currently licensed in the European Member States, Great Britain, Iceland, Liechtenstein, Northern Ireland and Norway.
Registration conditions differ internationally; always consult local prescribing information and/or Summary of Product Characteristics before prescribing any product.
Register now to unlock the content
Register now to access the content on this page
If not, register below
MED-ALL-AADC-2200023 | October 2023
Sign in or register to access exclusive content on this site